⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434293 | 0.73 | — | — | |
| SCHEMBL51249 | 0.73 | — | — | |
| SCHEMBL15898 | 0.70 | — | — | |
| SCHEMBL31299 | 0.68 | — | — | |
| SCHEMBL3387 | 0.64 | — | — | |
| SCHEMBL2554291 | 0.64 | — | — | |
| SCHEMBL7562766 | 0.62 | — | — | |
| SCHEMBL6517038 | 0.60 | — | — | |
| SCHEMBL1762395 | 0.60 | — | — | |
| SCHEMBL2640146 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | claimed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | claimed |
| EP-3423437-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | claimed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | claimed |
| WO-2018137036-A1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2018-08-02 | — | — | WO | claimed |
| WO-2016123709-A1 | FLUORINATED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS INHIBITORS OF BROMODOMAIN CONTAINING PROTEINS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | claimed |
| US-20080004288-A1 | Indazole Sulphonamide Derivatives | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | claimed |
| EP-1814863-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | claimed |
| WO-2006052190-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | claimed |
| US-4845097-A | AGRICULTURE | SANKYO COMPANY LIMITED (JP) | 1989-07-04 | — | — | US | claimed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230125917-A1 | METHOD OF TREATING MICROBIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-27 | — | — | US | disclosed |
| EP-4161481-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | The Rockefeller University (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-0882701-A1 | SUBSTITUTED AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0882703-A1 | CYCLIC AMIC ACID DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0196524-B1 | PHENOXYALKYLAMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND INSECTICIDAL AND ACARICIDAL COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
| US-4845097-A | AGRICULTURE | SANKYO COMPANY LIMITED (JP) | 1989-07-04 | — | — | US | disclosed |
| EP-0196524-A2 | Phenoxyalkylaminopyrimidine derivatives, their preparation and insecticidal and acaricidal compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-10-08 | — | — | EP | disclosed |